Israeli salvia-derived compounds as caffeine enhancers

Overview

This research program focuses on identifying and isolating bioactive compounds from Israeli Salvia species that modulate the activity of CYP1A2, the primary enzyme responsible for caffeine metabolism in humans. By partially inhibiting or modulating CYP1A2, these natural compounds can slow caffeine breakdown, thereby extending the duration and intensity of caffeine's physiological effects. The discovery creates an opportunity to develop natural, plant-derived caffeine enhancers for incorporation into functional beverages, energy products, dietary supplements, and pharmaceutical adjuvants.

The value proposition centers on offering a natural alternative to synthetic caffeine boosters, appealing to consumers seeking clean-label and plant-based ingredients. Israeli Salvia species represent an underexplored botanical source with potential advantages in compound diversity, regional uniqueness, and supply chain differentiation.

Technical specifications

Key research findings and capabilities:

• Identification of diterpenes similar to tanshinone and phenolic compounds within Israeli Salvia species that interact with CYP1A2
• LC-MS-based compound profiling and characterization of bioactive fractions
• Bioassay-guided fractionation using flash chromatography and preparative HPLC to isolate active compounds
• Enzymatic and cellular CYP1A2 activity models including liver microsome assays and HepG2 cell lines transfected with CYP1A2 gene variants
• Molecular docking studies to evaluate selectivity for caffeine metabolism versus other CYP1A2 substrates such as clozapine and phenacetin
• Kinetic characterization of inhibitory effects to understand temporal interactions

Potential applications:

• Functional beverages and energy drinks seeking extended caffeine efficacy
• Dietary supplements targeting alertness and cognitive performance
• Natural caffeine-potentiating ingredients for clean-label product formulations

Technology readiness level

The research is currently at an early-to-mid stage of development. Initial compound identification and tentative CYP1A2 modulating activity have been established. A 12 to 18 month validation plan is underway to isolate individual bioactive compounds, characterize their inhibitory kinetics, and confirm selectivity for caffeine metabolism over pharmaceutical substrates. Upon completion, the program aims to deliver characterized compounds and/or defined mixtures suitable for formulation development and further commercial evaluation.